Shinichi Komiyama

Dr. Shinichi Komiyama

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1999 in Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
SKShinichi Komiyama
Shinichi Komiyama
DADaisuke Aoki
Daisuke Aoki
ETEiichiro Tominaga
Eiichiro Tominaga
NSNobuyuki Susumu
Nobuyuki Susumu
YUYasuhiro Udagawa
Yasuhiro Udagawa
SNShiro Nozawa
Shiro Nozawa

3 May 2016 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SKShinichi Komiyama
Shinichi Komiyama
HKHidetaka Katabuchi
Hidetaka Katabuchi
MMMikio Mikami
Mikio Mikami
SNSatoru Nagase
Satoru Nagase
AOAikou Okamoto
Aikou Okamoto
HYHiroyuki Yoshikawa
Hiroyuki Yoshikawa

20 July 2018 in International Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
SKShinichi Komiyama
Shinichi Komiyama
KKKazuyoshi Kato
Kazuyoshi Kato
YIYuki Inokuchi
Yuki Inokuchi
HTHirokuni Takano
Hirokuni Takano
TMTakashi Matsumoto
Takashi Matsumoto
TSToru Sugiyama
Toru Sugiyama
Background This was the first large-scale prospective observational Japanese study evaluating the safety and efficacy of bevacizumab combined with paclitaxel and carboplatin for newly diagnosed advanced ovarian cancer. Methods Patients were prospectively enrolled in the primary analysis cohort if they had Stage III or IV epithelial ovarian/fallopian tube/primary peritoneal cancer and were scheduled to receive paclitaxel plus carboplatin every 3 weeks in Cycles 1–6 and bevacizumab every 3 weeks in Cycles 2–22. Primary endpoints were bevacizumab-specific adverse events and adverse events ≥ Grade 3. Secondary endpoints were progression-free survival (PFS) and the response rate. Results Among 346 patients enrolled, 293 patients formed the primary analysis cohort. Regarding bevacizumab-specific adverse events ≥ grade 3, incidence rates of thromboembolic events (1.4%), gastrointestinal perforation (0.3%), fistula (0.7%), wound dehiscence (0%), and bleeding (0%) were very low. While incidence rates of hypertension (23.2%) and proteinuria (12.6%) were high, all such events were tolerable. No patient with prior bowel resection developed perforation or fistula. Median PFS was 16.3 months (95% CI 14.5–18.9). The response rate was 77.5% (95% CI 67.4–85.7). The response rate was 63.6% in patients with clear cell carcinoma, which tended to be better than previously reported. The median platinum-free interval was 11.5 months, and the platinum-resistant recurrence rate was 24.5%. Conclusions Combining bevacizumab with chemotherapy was tolerable and efficacy was acceptable in Japanese patients with advanced epithelial ovarian cancer. Bevacizumab seems to reduce platinum-resistant recurrence and is promising for clear cell carcinoma.

11 November 2010 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SNSatoru Nagase
Satoru Nagase
HKHidetaka Katabuchi
Hidetaka Katabuchi
MHMasamichi Hiura
Masamichi Hiura
NSNoriaki Sakuragi
Noriaki Sakuragi
YAYoichi Aoki
Yoichi Aoki
NYNobuo Yaegashi
Nobuo Yaegashi

30 October 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
TSTadahiro Shoji
Tadahiro Shoji
TETakayuki Enomoto
Takayuki Enomoto
MAMasakazu Abe
Masakazu Abe
AOAikou Okamoto
Aikou Okamoto
TNTakayuki Nagasawa
Takayuki Nagasawa
TSToru Sugiyama
Toru Sugiyama
We investigated the efficacy and safety of further bevacizumab therapy in patients with platinum‐resistant ovarian cancer whose disease had progressed after bevacizumab plus chemotherapy. In this multicenter, open‐label, phase II trial (JGOG3023), patients were randomized 1:1 to a single‐agent chemotherapy alone (either pegylated liposomal doxorubicin [40 or 50 mg/m2 administered intravenously], topotecan [1.25 mg/m2 intravenously], paclitaxel [80 mg/m2 intravenously], or gemcitabine [1000 mg/m2 intravenously]) or single‐agent chemotherapy + bevacizumab (15 mg/m2 intravenously). The primary endpoint was investigator‐assessed progression‐free survival (PFS) according to RECIST version 1.1. Secondary endpoints were overall survival (OS), objective response rate (ORR), and response rate according to Gynecological Cancer Intergroup cancer antigen 125 criteria. In total, 103 patients were allocated to chemotherapy (n = 51) or chemotherapy + bevacizumab (n = 52). Median investigator‐assessed PFS was 3.1 and 4.0 mo in each group, respectively (hazard ratio [HR] = 0.54, 95% confidence interval [CI]: 0.32‐0.90, P = .0082). Median OS was 11.3 and 15.3 mo in each group, respectively (HR = 0.67, 95% CI: 0.38‐1.17, P = .1556). Respective ORRs were 13.7% and 25.0% (P = .0599) and response rates were 16.7% and 21.4% (P = .8273). The incidence of grade ≥3 treatment‐related AEs was 42.0% in the chemotherapy group and 54.9% in the chemotherapy + bevacizumab group; AEs were well tolerated, with only 2 and 12 events leading to discontinuation of therapy, respectively. Bevacizumab was effective beyond progressive disease and AEs were manageable. The observed improvement in PFS requires further verification.

1 April 2003 in International Journal of Gynecological Pathology
Verified
Journal Article
Closed access
MMMikio Mikami
Mikio Mikami
CTChisei Tei
Chisei Tei
KTKyoko Takehara
Kyoko Takehara
SKShinichi Komiyama
Shinichi Komiyama
ASAtsushi Suzuki
Atsushi Suzuki
THTakanori Hirose
Takanori Hirose
A 38-year-old female presented with a lower abdominal mass. During the operation the mass was found to be retroperitoneal and was excised. Gross examination revealed a mucin-containing cystic lesion with a mural nodule. On microscopic examination, the cystic areas were lined by an invasive mucinous adenocarcinoma and the nodule was composed of an anaplastic sarcomatoid tumor that was immunoreactive for cytokeratin. This present case is the 21st example of a retroperitoneal primary mucinous cystadenocarcinoma and the fourth with a mural nodule. Three of four cases with a mural nodule, including our case, had a rapidly fatal outcome.